The influential "Antibodies to Watch" series wasn't a strategic initiative. Editor Janice Reichert created it herself to fill an issue when authors grew hesitant to submit papers due to a delay in the new journal's PubMed indexing. This crisis-driven solution became a cornerstone of the publication.
China's rise as a biotech power wasn't accidental. It was driven by strategic five-year plans that boosted R&D and manufacturing, and crucially, streamlined regulatory approvals. The time to approve an Investigational New Drug (IND) application dropped from several years to just a few months, fueling rapid development.
The Antibody Society's creation was catalyzed by the shocking 2006 TGN1412 incident, where a first-in-human study nearly killed six participants. This crisis introduced profound uncertainty into the field, prompting founder Jim Houston to establish a focused nonprofit to address the industry's shared concerns and foster collaboration.
The publisher of MABS specifically sought an editor-in-chief who had a global overview of antibody therapeutics but was not based at a company. This strategy of selecting a neutral, third-party academic researcher ensured the journal would be perceived as reputable, authoritative, and unbiased, which was key to its success.
A 2001 report showing humanized antibodies had higher approval success rates than murine versions was a pivotal "eye-opener." While seemingly obvious today, this data, published by a reputable academic group, provided the critical external validation needed at the time to justify major investments into new antibody technologies and development programs.
To maintain scientific integrity, the journal MABS uses a rigorous five-round manuscript evaluation. This process involves an initial check, an assistant editor assessment, peer review, author revision, and a final editor's polish. This deep, human-led scrutiny serves as a robust filter against low-quality, AI-generated content.